AB740
Anti-Apolipoprotein A-I Antibody
serum, Chemicon®
Synonym(s):
ApoAI
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
biological source
goat
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Application
This Anti-Apolipoprotein A-I Antibody is validated for use in WB for the detection of Apolipoprotein A-I.
Biochem/physiol Actions
Human apolipoprotein A-I. Monospecific by IEP.
Physical form
Goat serum defibrinated, delipidized and adsorbed by solid phase chromatography as required. Liquid in 0.05M Tris-HCl, pH 7.5, 0.5M NaCl with 0.1% sodium azide.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker.
Lepedda, AJ; Nieddu, G; Zinellu, E; De Muro, P; Piredda, F; Guarino, A; Spirito, R; Carta et al.
Oxidative Medicine and Cellular Longevity null
Ronald W Clark et al.
Journal of lipid research, 47(3), 537-552 (2005-12-06)
We have identified a series of potent cholesteryl ester transfer protein (CETP) inhibitors, one member of which, torcetrapib, is undergoing phase 3 clinical trials. In this report, we demonstrate that these inhibitors bind specifically to CETP with 1:1 stoichiometry and
Antonio Junior Lepedda et al.
Journal of circulating biomarkers, 8, 1849454419875912-1849454419875912 (2019-10-08)
Myasthenia gravis (MG) is an autoimmune disease leading to varying degrees of skeletal muscle weakness. It is caused by specific antibodies directed against definite components in the postsynaptic membrane at the neuromuscular junction (NMJ), such as the acetylcholine receptor (AChR)